NCT01260324

Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

The Detection and Epidemiology of NAION in a Commercially Insured Population in the United States.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 21,283 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objectives of this study were to: (1) evaluate the natural history of non-arteritic anterior ischemic optic neuropathy (NAION); (2) estimate the population incidence of NAION; and (3) identify potential risk factors for NAION.

Detailed description

The study population consisted of members of the Ingenix Normative Health Informatics (NHI) Database during 01/01/2003 through 12/31/2007, who were 18 years of age or older with at least 183 days of continuous enrollment in the database and without any doctor visits associated with a diagnosis of ischemic optic neuropathy during the 183 days prior to cohort entry. From the study population, patients with a claim associated with an ischemic optic neuropathy diagnosis code were identified as potential NAION cases (n = 3,732). From the potential NAION cases, definite and possible NAION cases were identified using medical record review and a claims algorithm (n=1,283). From the study population, patients without a claim associated with an ischemic optic neuropathy diagnosis code were randomly selected as controls (n = 20,000)

Conditions

• Anterior Ischemic Optic Neuropathy
• Ischemic Optic Neuropathy

Interventions

Type	Name	Description
OTHER	No intervention given in this observational study	No intervention given in this observational study
OTHER	No intervention given in this observational study	No intervention given in this observational study

Timeline

• Start date: 2008-08-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2010-12-15
• Last updated: 2021-02-01
• Results posted: 2011-04-25